EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparative Performance of Urine Lipoarabinomannan and Urine Xpert MTB/RIF Ultra for Diagnosing Tuberculosis in Adult Inpatients With HIV in East London, South Africa

David Stead iD, Sean Wasserman iD, Ebrahim Steenkamp iD, Andy Parrish iD, David Barr iD, Graeme Meintjes iD

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf080 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von David Stead und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Frere and Cecilia Makiwane Hospitals, East London, South Africa. Hauptthemen laut MEDLINE: Lipopolysaccharides, HIV Infections, Tuberculosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust, Collaborating Centres Programme, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Urine lateral flow lipoarabinomannan (LF-LAM) is a point-of-care tuberculosis (TB) test for patients with human immunodeficiency virus (HIV). Xpert MTB/RIF Ultra (Ultra) has improved sensitivity on sputum compared with the previous generation of Xpert and may improve diagnostic yield for TB on urine-based testing.

Methods

We conducted a diagnostic accuracy study in East London, South Africa. Adults with HIV hospitalized with ≥1 W4SS (World Health Organization–recommended 4-symptom screen) or clinical concern for TB were enrolled; TB cultures were performed on blood, sputum, and urine. Unprocessed urine was tested with LF-LAM and Ultra on the pellet of 15 mL centrifuged urine. The primary outcome was sensitivity of urine Ultra compared with LF-LAM, with microbiological TB (positive TB culture or molecular test, excluding urine Ultra) as the reference. Secondary outcomes included specificity and diagnostic yield.

Results

Two hundred thirty-eight participants were enrolled with a median CD4 count of 76 cells/mm3. Microbiological TB was diagnosed in 62 (26%). Using microbiological TB as the reference, sensitivity of LF-LAM and urine Ultra was 45% (95% confidence interval, 32–58) and 70% (95% CI, 57–81; McNemar P = .0013); specificity was 93% (95% CI, 81–99) and 100% (95% CI, 92–100; McNemar P = .25). Diagnostic yields for microbiological TB were 34% for sputum Ultra, 45% for urine LF-LAM, 68 for urine Ultra, and 73% for urine LF-LAM and urine Ultra combined.

Conclusions

Combined urine-based testing (Ultra + LF-LAM) identified nearly three-quarters of medical inpatients with HIV with microbiological TB. Urine Ultra had significantly improved sensitivity compared with LF-LAM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipopolysaccharidesHIV InfectionsTuberculosisHumansAdultMaleFemaleSensitivity and SpecificitySouth AfricaMiddle AgedMycobacterium tuberculosisSputumInpatientsLondon

Stichwörter der Autor:innen

HIVLipoarabinomannanXpert MTB/RIF Ultrahospitalisedurine TB diagnostics

Substanzen

lipoarabinomannanLipopolysaccharides

Autor:innen und Institutionen

  • Department of Medicine, Frere and Cecilia Makiwane Hospitals, East London, South Africa.
  • Department of Medicine, Faculty of Health Sciences, Walter Sisulu University, Mthatha, South Africa.
  • Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Institute for Infection and Immunity, St George's, University of London, London, United Kingdom.
  • Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa.
  • Department Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, United Kingdom.

ORCID-Profile: David Stead, Sean Wasserman, Ebrahim Steenkamp, Andy Parrish, David Barr, Graeme Meintjes

Förderung

  • Wellcome Trust
  • Collaborating Centres Programme
  • NIH HHS
  • NIAID NIH HHS
  • FIC NIH HHS
  • National Research Foundation
  • South African Research Chairs Initiative of the Department of Science and Technology
  • South African Medical Research Council

Zitieren

APA

Stead, D., Wasserman, S., Steenkamp, E., Parrish, A., Barr, D., & Meintjes, G. (2025). Comparative Performance of Urine Lipoarabinomannan and Urine Xpert MTB/RIF Ultra for Diagnosing Tuberculosis in Adult Inpatients With HIV in East London, South Africa. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf080

Vancouver

Stead D, Wasserman S, Steenkamp E, Parrish A, Barr D, Meintjes G. Comparative Performance of Urine Lipoarabinomannan and Urine Xpert MTB/RIF Ultra for Diagnosing Tuberculosis in Adult Inpatients With HIV in East London, South Africa. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf080

BibTeX
@article{Stead2025,
  author = {Stead, David and Wasserman, Sean and Steenkamp, Ebrahim and Parrish, Andy and Barr, David and Meintjes, Graeme},
  title = {Comparative Performance of Urine Lipoarabinomannan and Urine Xpert MTB/RIF Ultra for Diagnosing Tuberculosis in Adult Inpatients With HIV in East London, South Africa},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf080}
}
Kostenlos starten →